FAR HILLS, New Jersey- (BUSINESS WIRE) – Samsara Vision, a company focused on restoring vision and freedom to patients with late-stage, age-related macular degeneration (AMD) with advanced visual prostheses, today announced the first three successful clinical cases in Italy using SING IMT ™. (New Generation Implant Miniature Telescope with Small Incision) for people living with late-stage age-related macular degeneration (AMD). SING IMT ™ was successfully implanted in patients in early February by Professor Stanislao Rizzo, Director of the Ophthalmology Department of the Agostino Gemeli University Polyclinic Foundation IRCCS and the Ophthalmology Clinic on the campus of the Catholic University of Rome.
Almost invisible inside the eye, SING IMT ™ is a Galileo telescope implant designed to improve visual acuity and quality of life in patients with late-stage AMD. SING IMT, which consists of ultra-precise micro-optics, is implanted during a typical outpatient cataract surgery. After recovery after surgery, patients work closely with a visually impaired specialist and occupational therapist to learn how to use their new vision, often practicing exercises tailored to their specific vision goals. Images that are visible in “direct” vision are magnified 2.7 times and projected onto healthy, intact areas of the macula in the back of the eye, reducing the effect of AMD’s “blind spot” on central vision and allowing patients to see images that may be previously unrecognizable.
«It is incredibly interesting to present SING IMT ™ as a treatment option to patients in Italy whose vision has been severely impaired due to AMD at a late stage. Macular degeneration not only deprives people of vision but also independence, as they have to rely on what others read to them or describe what is in front of them. It can be isolating, ”Professor Ritsa explained. «It is a great honor for me to offer my patients high-quality care and access to the most advanced treatment options. I hope that these first three patients are just the first of many who will experience improved vision and then reconnect with the people and occupations they enjoy. ”
Advanced technology restores vision to the elderly
The main cause of blindness in the elderly, late-stage AMD, is a disease that can lead to loss of central or “direct” vision, creating a blind spot that cannot be corrected with glasses, medications, injections, or cataract surgery. Other currently available treatments for late-stage AMD, such as intraocular injections, may slow or delay disease progression but do not have a direct effect on the vision restoration that SING IMT ™ offers to eligible candidates. This blind spot makes it difficult or impossible for patients to recognize faces, read, and perform daily tasks such as watching TV, cooking, and self-care. A study published in the British Journal of Ophthalmology found that approximately 67 million people in the European Union suffer from AMD, and that number is expected to grow by 15 per cent by 2050.
«We are pleased that Professor Stanislau Rizza reports on the encouraging results of the first three Italian clinical cases using SING IMT ™, and appreciates his enthusiasm for providing the latest ophthalmic innovations to patients in Italy, ”said Dr. Mauro Arcier, Director of Global Market Development. , Samsara Vision. «We are also currently working with other key opinion leaders across Europe to bring our new life-changing technologies to their patients and meet the needs of these older people who want to see more and better, thereby improving their quality of life ”.
Because AMD is a progressive disease, over time patients have adapted to vision loss in the central visual field. Before receiving SING IMT ™, patients should understand the possible and realistic results after surgery and commit to working with their ophthalmic team to use visual techniques and exercises to maximize the effectiveness of SING IMT ™. Patients must also meet the age, vision, corneal condition and other requirements noted in the patient information booklet to determine whether they are candidates for SING IMT ™.
The telescopic implant is not a cure for the late stage of AMD. It will not return your vision to the level that the patient had before AMD, and does not fully compensate for vision loss. The most common risks of SING IMT operation запа include inflammatory deposits or deposits on the device and increased intraocular pressure. Significant side effects include corneal edema, corneal edema that impairs vision, corneal transplantation, and decreased visual acuity. There is a risk that telescope implant surgery may worsen vision rather than improve it. Individual results may vary.
SING IMT ™ approved for patients with late-stage AMD who are 55 years of age or older in CE-referenced countries, and it is not currently FDA-approved in the United States. To learn more about SING IMT ™, visit http://singimt.samsaravision.com
About Samsara Vision
Samsara Vision is a privately held medical device company headquartered in the United States and researches, develops, manufactures and markets patented implanted ophthalmic devices and technologies designed to significantly improve the vision and quality of life of people with retinal detachment. . disorders. We believe that rejuvenating vision revitalizes the spirit, allowing people to reconnect to the things in life that they love to see and do. Our approach includes working with healthcare professionals, researchers, payers and advocates to ensure that people living with impaired vision have access to our new technologies and support pathways, thereby better securing the future they can see through -new. Find out more at https://www.samsaravision.com
Safe Harbor Statement
This press release contains explicit or implicit statements about the future under U.S. federal securities laws. Predictive statements include the belief that changing the company name better reflects Samsara’s patience and determination, as well as the belief that rejuvenating vision revitalizes the spirit, allowing people to reconnect to the things in life they love to see and do. These forward-looking statements and their implications are based solely on the current expectations of Samsara’s management and are subject to a number of factors and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, may lead to the fact that the actual results differ significantly from those described in the forward-looking statements: claims of other companies and individuals regarding the ownership of intellectual property; changes in technology and market requirements; Samsara may face delays or obstacles in launching and / or successfully completing its clinical trials; Samsara products cannot be approved by regulators, Samsara technology cannot be validated as it develops, and its methods may not be accepted by the scientific community; Samsara may be unable to retain or engage key employees whose knowledge is needed to develop its products; unforeseen scientific difficulties may arise with the Samsara process; Samsara products may turn out to be more expensive than she thinks; laboratory results may not lead to equally good results in real clinical settings; the results of preclinical studies may not correlate with the results of clinical trials in humans; Samsara patents may not be enough; Samsara products can harm recipients; changes in legislation could negatively affect Samsara; inability to timely develop and implement new technologies, products and applications; loss of market share and pressure on pricing as a result of competition, which may result in Samsara’s actual results or performance differing significantly from those provided for in such forward-looking statements. Unless otherwise required by law, Samsara undertakes no obligation to publicly disclose any changes to these forward-looking statements to reflect events or circumstances beyond that date or to reflect the occurrence of unforeseen events.